Axura

RSS

memantine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Axura. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Axura.

This EPAR was last updated on 10/07/2018

Authorisation details

Product details
Name
Axura
Agency product number
EMEA/H/C/000378
Active substance
memantine hydrochloride
International non-proprietary name (INN) or common name
memantine
Therapeutic area (MeSH)
Alzheimer Disease
Anatomical therapeutic chemical (ATC) code
N06DX01
Publication details
Marketing-authorisation holder
Merz Pharmaceuticals GmbH
Revision
24
Date of issue of marketing authorisation valid throughout the European Union
16/05/2002
Contact address
Eckenheimer Landstr. 100
D-60318 Frankfurt
Germany

Product information

25/06/2018 Axura - EMEA/H/C/000378 - IB/0079

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

other antidementia drugs

Therapeutic indication

Treatment of patients with moderate to severe Alzheimer's disease.

Assessment history

How useful was this page?

Add your rating